HOOKIPA Pharma to Host Investor Call on HB-200 Data from ASCO 2024

NEW YORK and VIENNA, May 30, 2024 — HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company focused on developing innovative immunotherapies based on its proprietary arenavirus platform, has announced an upcoming investor call. The call, to be held on June 4, 2024, at 4:15 p.m. ET, will be led by members of the company's Executive Team. They will discuss preliminary Phase 2 clinical data for HB-200 in combination with pembrolizumab for treating human papillomavirus 16 (HPV16) positive head and neck cancer. This update includes promising preliminary results concerning progression-free survival and overall survival for patients with a combined positive score (CPS) of 20 or higher.

The investor call, titled "HOOKIPA HB-200 ASCO Data Update," will provide detailed insights into the efficacy of HB-200 when used in conjunction with pembrolizumab. Interested parties can register for the webcast or dial-in for the call to join the discussion.

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, specializes in creating novel immunotherapies that mobilize and amplify targeted T cells to fight and prevent serious diseases. The company's proprietary arenavirus platform includes both replicating and non-replicating technologies designed to induce strong and long-lasting antigen-specific CD8+ T cell responses, as well as pathogen-neutralizing antibodies.

HOOKIPA's product pipeline features investigational arenaviral immunotherapies targeting HPV16-positive cancers, KRAS-mutated cancers, and other unspecified indications. The company is also working on developing functional cures for hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in collaboration with Gilead Sciences.

The anticipated investor call on June 4 is set to highlight the initial results from the Phase 2 clinical trials, which are crucial for advancing HB-200 through the clinical development process. These findings represent a significant milestone for HOOKIPA, showcasing the potential of their innovative immunotherapies to positively impact patient outcomes and alter the course of disease.

It is important to note that the statements made during the call will include forward-looking information as defined by the Private Securities Litigation Reform Act of 1995. These statements, identified by terms such as "anticipates," "believes," "expects," and similar expressions, involve significant risks and uncertainties. Factors such as the early stage of development, the design and conduct of preclinical and clinical trials, regulatory approval processes, and the challenges in manufacturing drug products could cause actual outcomes to differ from the forward-looking statements.

HOOKIPA is committed to updating its stakeholders and the public through various communication channels, including SEC filings, press releases, public conference calls, webcasts, and social media. The company encourages investors and other interested parties to stay informed by reviewing the information available on these platforms.

In conclusion, the upcoming investor call by HOOKIPA Pharma Inc. is poised to provide critical updates on the progress of HB-200 in combination with pembrolizumab for HPV16 positive head and neck cancer. The promising preliminary data on progression-free and overall survival rates for patients with CPS ≥20 marks a pivotal development in the company's ongoing efforts to develop effective immunotherapies for serious diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!